Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2099MR)

This product GTTS-WQ2099MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2099MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10563MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ2817MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ1058MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ1934MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ5707MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ7976MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ4010MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ11631MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW